Journal
/
/
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
JoVE Journal
Immunology and Infection
A subscription to JoVE is required to view this content.  Sign in or start your free trial.
JoVE Journal Immunology and Infection
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
DOI:

10:03 min

August 01, 2013

, , ,

Chapters

  • 00:05Title
  • 01:36Arenavirus Rescue Transfection
  • 04:41Confirmation of Recombinant Arenavirus Rescue
  • 07:11r3LCMV and r3Candid#1 Viral Rescue
  • 08:06Results: Arenavirus in Vero Cells
  • 09:30Conclusion

Summary

Automatic Translation

Rescue of recombinant arenaviruses from cloned cDNAs, an approach referred to as reverse genetics, allows researchers to investigate the role of specific viral gene products, as well as the contribution of their different specific domains and residues, to many different aspects of the biology of arenavirus. Likewise, reverse genetics techniques in FDA-approved cell lines (Vero) for vaccine development provides novel possibilities for the generation of effective and safe vaccines to combat human pathogenic arenaviruses.

Related Videos

Read Article